Brexit readiness: what’s your EU QP and Batch Release site …
GMP News: What does Brexit mean for the QP?, QP Association – Brexit related Information, QP Association – Brexit related Information, Following Brexit, QP batch release will need to be performed within the EU for EU markets under a manufacturer’s/importer’s authorisation (MIA) that is held by a legal entity with the EU. A large number of companies are choosing to relocate the responsibility for EU batch certification of medicinal products from the UK to Ireland.
As the role of the QP is already enshrined in UK law, if the UK agrees to abide by EU legislation, there should be no change of the roles or responsibilities of the QP. However, after Brexit unless there is some sort of bilateral agreement it may not be possible for UK QPs to work in Europe, and vice-versa.
4 October 2018. Pharmacovigilance: Be prepared for Hard Brexit. The UK Government has released some information regarding the consequences of the Brexit on pharmacovigilance and the establishment of the Qualified Person for Pharmacovigilance (QPPV). 25 September 2018.
6/25/2018 · If a clinical trial sponsor is using the U.K. as the supply route, then that currently approved route may be at risk. Essentially, if currently located in the U.K. and a “hard Brexit” occurs, you will have to relocate your QP release and clinical trial distribution to take place within an EU country.
1/1/2021 · The below guidance should be followed from 1 January 2021. It replaces previously published guidance on what to do from the end of the transition period.
8/14/2017 · The release process for IMPs differs from that for authorised medicinal products in that there is a requirement for both the QP certification and release by the Sponsor following fulfilment of the requirements of Article 9 of Directive 2001/20/EC.
1/1/2021 · From 1 January 2021, a wholesale dealer in Great Britain may only import Qualified Person ( QP ) certified medicines from the European Economic Area ( EEA) if certain checks are made by the ‘Responsible Person (import) ( RPi )’. Great Britain is England, Wales and Scotland. This guidance describes how you can apply to be a RPi, and how to …
9/1/2019 · This includes MAHs who have permission to perform quality control testing in the UK even after Brexit . The EMA has communicated that “The transfer should be completed quickly and in principle by the end of 2019 at the latest”. Q: Can you summarise what PharmaLex has been doing to assist companies in their Brexit readiness?
